Literature DB >> 20375333

Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype.

Pradeep Mettu1, Elvira Agrón, Sonia Samtani, Emily Y Chew, Wai T Wong.   

Abstract

PURPOSE: von Hippel-Lindau (VHL) disease is a dominantly inherited, multisystemic tumor syndrome caused by mutations in the VHL gene. This study was conducted to establish genotype-phenotype correlations between the positions of disease-causing missense mutations and the ocular phenotypes of VHL disease.
METHODS: Participants with clinically defined VHL disease and documented germline missense mutations in the VHL gene were identified in a cross-sectional study (n=412). Statistical analysis was used to correlate the position of the missense mutation in either the alpha- or beta-domain of the VHL protein with the ocular disease phenotype.
RESULTS: Missense mutations among study participants were located in 47 of the 213 possible codons in the VHL gene. Almost all mutations (98.5%) were located in one of two structural domains of the VHL protein: the alpha- and beta-domains. alpha-Domain mutations were significantly associated with a higher prevalence of retinal capillary hemangioblastomas (RCHs) compared with the beta-domain mutations (P=0.016). Among patients with RCHs, the prevalence of the lesions in the juxtapapillary position was also significantly higher in patients with alpha-domain mutations (P=0.0017). Conversely, beta-domain mutations correlated with a higher prevalence of peripherally located RCHs (P=0.0104).
CONCLUSIONS: The location of missense mutations in the VHL gene correlates significantly with the prevalence and phenotype of ocular disease, and as such, influences the risk of visual loss in affected patients. These genotype-phenotype correlations can assist in the prognostic counseling and follow-up of VHL patients and may provide a basis for molecular inferences on ocular VHL disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20375333      PMCID: PMC2941163          DOI: 10.1167/iovs.10-5223

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  39 in total

1.  Juxtapapillary capillary hemangiomas. Clinical features and visual acuity outcomes.

Authors:  C M McCabe; H W Flynn; C L Shields; J A Shields; C D Regillo; H R McDonald; M H Berrocal; J D Gass; W F Mieler
Journal:  Ophthalmology       Date:  2000-12       Impact factor: 12.079

2.  Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.

Authors:  M Ohh; C W Park; M Ivan; M A Hoffman; T Y Kim; L E Huang; N Pavletich; V Chau; W G Kaelin
Journal:  Nat Cell Biol       Date:  2000-07       Impact factor: 28.824

3.  Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.

Authors:  M Ohh; Y Takagi; T Aso; C E Stebbins; N P Pavletich; B Zbar; R C Conaway; J W Conaway; W G Kaelin
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 4.  Genotype-phenotype correlation in von Hippel-Lindau syndrome.

Authors:  C A Friedrich
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

Review 5.  von Hippel-Lindau disease.

Authors:  A D Singh; C L Shields; J A Shields
Journal:  Surv Ophthalmol       Date:  2001 Sep-Oct       Impact factor: 6.048

6.  Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.

Authors:  S C Clifford; M E Cockman; A C Smallwood; D R Mole; E R Woodward; P H Maxwell; P J Ratcliffe; E R Maher
Journal:  Hum Mol Genet       Date:  2001-05-01       Impact factor: 6.150

7.  Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study.

Authors:  Hélène Dollfus; Pascale Massin; Pierre Taupin; Catherine Nemeth; Sandrine Amara; Sophie Giraud; Christophe Béroud; Pascal Dureau; Alain Gaudric; Paul Landais; Stéphane Richard
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-09       Impact factor: 4.799

8.  Benefits and complications of photodynamic therapy of papillary capillary hemangiomas.

Authors:  Ursula M Schmidt-Erfurth; Christine Kusserow; Irene A Barbazetto; Horst Laqua
Journal:  Ophthalmology       Date:  2002-07       Impact factor: 12.079

Review 9.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

Review 10.  Radiological evaluation, management, and surveillance of renal masses in Von Hippel-Lindau disease.

Authors:  M Meister; P Choyke; C Anderson; U Patel
Journal:  Clin Radiol       Date:  2008-12-18       Impact factor: 2.350

View more
  13 in total

Review 1.  Von Hippel-Lindau disease (VHL): a need for a murine model with retinal hemangioblastoma.

Authors:  Stanley Park; Chi-Chao Chan
Journal:  Histol Histopathol       Date:  2012-08       Impact factor: 2.303

2.  A meta-analysis of different von Hippel Lindau mutations: are they related to retinal capillary hemangioblastoma?

Authors:  Fatemeh Azimi; Ali Aghajani; Golnaz Khakpour; Samira Chaibakhsh
Journal:  Mol Genet Genomics       Date:  2022-08-25       Impact factor: 2.980

3.  Longitudinal analysis of retinal hemangioblastomatosis and visual function in ocular von Hippel-Lindau disease.

Authors:  Brian C Toy; Elvira Agrón; Divya Nigam; Emily Y Chew; Wai T Wong
Journal:  Ophthalmology       Date:  2012-08-17       Impact factor: 12.079

4.  Signaling pathways triggered by oxidative stress that mediate features of severe retinopathy of prematurity.

Authors:  Haibo Wang; Sarah X Zhang; Mary Elizabeth Hartnett
Journal:  JAMA Ophthalmol       Date:  2013-01       Impact factor: 7.389

5.  Germline mutation of Glu70Lys is highly frequent in Korean patients with von Hippel-Lindau (VHL) disease.

Authors:  Sena Hwang; Cheol Ryong Ku; Ji In Lee; Kyu Yeon Hur; Myung-Shik Lee; Chul-Ho Lee; Kyo Yeon Koo; Jin-Sung Lee; Yumie Rhee
Journal:  J Hum Genet       Date:  2014-07-31       Impact factor: 3.172

6.  Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-α binding site missense mutations elevate age-specific risk for CNS hemangioblastoma.

Authors:  Jee-Soo Lee; Ji-Hyun Lee; Kyu Eun Lee; Jung Hee Kim; Joon Mo Hong; Eun Kyung Ra; Soo Hyun Seo; Seung Jun Lee; Man Jin Kim; Sung Sup Park; Moon-Woo Seong
Journal:  BMC Med Genet       Date:  2016-07-20       Impact factor: 2.103

Review 7.  Von Hippel-Lindau Disease and the Eye.

Authors:  Saeed Karimi; Amir Arabi; Toktam Shahraki; Sare Safi
Journal:  J Ophthalmic Vis Res       Date:  2020-02-02

8.  Clinical and molecular characteristics of East Asian patients with von Hippel-Lindau syndrome.

Authors:  Meihua Wong; Ying-Hsia Chu; Hwei Ling Tan; Hideharu Bessho; Joanne Ngeow; Tiffany Tang; Min-Han Tan
Journal:  Chin J Cancer       Date:  2016-08-15

9.  Coexistence of VHL Disease and CPT2 Deficiency: A Case Report.

Authors:  Alfonso Massimiliano Ferrara; Monica Sciacco; Stefania Zovato; Silvia Rizzati; Irene Colombo; Francesca Boaretto; Maurizio Moggio; Giuseppe Opocher
Journal:  Cancer Res Treat       Date:  2016-03-25       Impact factor: 4.679

Review 10.  Ocular Manifestations of von Hippel-Lindau Disease.

Authors:  Misty D Ruppert; Meredith Gavin; Kelly T Mitchell; Alan N Peiris
Journal:  Cureus       Date:  2019-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.